Kairos Pharma Reports Promising Phase 2 Results for ENV-105 Prostate Cancer Treatment

Kairos Pharma Ltd. has reported encouraging interim results from its Phase 2 clinical trial of ENV-105 in men with metastatic castration-resistant prostate cancer, demonstrating significant clinical benefit and potential for restoring treatment responsiveness in patients who have exhausted standard options. The data, presented at the European Society for Medical Oncology meeting in Berlin, showed that 86% of patients treated with ENV-105 combined with apalutamide experienced clinical benefit, with all responders remaining progression-free for at least four months and half continuing beyond one year without disease progression.

The study's findings are particularly significant because seven of nine evaluable patients experienced prostate-specific antigen reductions, indicating the therapy's potential to restore hormone responsiveness in patients who have developed resistance to standard treatments. This represents a crucial advancement for prostate cancer patients who typically face limited options once their cancer becomes castration-resistant, a stage where the disease often progresses rapidly and treatment alternatives dwindle.

ENV-105, also known as carotuximab, represents a novel approach to cancer treatment by targeting CD105, a protein identified as a key driver of resistance to various cancer therapies. According to company information available at https://ibn.fm/1KEqw, elevation of CD105 in response to standard therapy frequently results in resistance and disease relapse. The antibody aims to reverse this drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types.

The ongoing randomized trial, led by Cedars-Sinai and partner institutions, continues to enroll patients to further evaluate safety and long-term efficacy. For investors and stakeholders seeking additional information about Kairos Pharma, the company maintains its newsroom at https://ibn.fm/KAPA where updates are regularly posted. The positive interim results suggest ENV-105 could address significant unmet medical needs in prostate cancer treatment, particularly for patients who have developed resistance to existing therapies.

This development comes at a critical time when prostate cancer remains one of the most common cancers in men worldwide, with castration-resistant prostate cancer representing an advanced stage where treatment options are limited and outcomes are often poor. The ability to restore hormone sensitivity could potentially transform treatment paradigms and extend survival for patients facing this challenging disease stage. The continued enrollment in the Phase 2 trial will provide additional data to validate these initial promising results and potentially support further clinical development.